Extramural Venous Invasion as Prognostic Factor of Recurrence in Stage 1 and 2 Colon Cancer

• Published in: Gastroenterology research and practice Vol. 2017; no. 2017; pp. 1 - 6
• Main Authors: Loffeld, Ruud J. L. F., Mulder, M. M. R., Flens, M. J., van Eeghen, E. E.
• Format: Journal Article
• Language: English
• Published: Cairo, Egypt Hindawi Publishing Corporation 01.01.2017; Hindawi; Hindawi Limited; Wiley
• Subjects: Age; Cancer invasiveness; Cancer recurrence; Cancer research; Cancer therapies; Colorectal cancer; Comorbidity; Development and progression; Disease; Health aspects; Histopathology; Lymphatic system; Medical prognosis; Pathology; Patients; Prognosis; Risk factors; Stains & staining; Studies; Veins; Netherlands
• ISSN: 1687-6121; 1687-630X
• DOI: 10.1155/2017/1598670

Aim. Extramural venous invasion (EMVI) is a prognostic indicator in patients with colorectal cancer. However, its additional value in patients with stage 1 and 2 colorectal cancer is uncertain. In the present study, the incidence of EMVI and the hazard ratio for recurrence in patients with stage 1 and 2 colon cancer were studied. Methods. 184 patients treated for stage 1 and 2 colon cancer were included with a follow-up of at least 5 years. Chart review was performed and EMVI was assessed by two separate pathologists. EMVI was scored with additional caldesmon staining on the resection specimen. Primary outcomes were recurrence-free survival (RFS) measured through the Cox regression analysis and prevalence of EMVI. Results. There were 10 cases of EMVI and 3 cases of intramural venous invasion (IMVI) all occurring in patients with stage 2 disease corresponding to a prevalence of 9%. Thirty-one percent of the patients with venous invasion experienced recurrence versus 14% in patients without, corresponding with a hazard ratio of 2.39 (p=0.11). Conclusion. The present study demonstrates a trend towards an increased risk of recurrence in patients with stage 2 colon cancer with venous invasion. This warrants consideration of adjuvant chemotherapy despite the lack of lymph node metastases.